Cohance Lifesciences Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹441.90
Market cap
16,907 Cr
Stock P/E
127.4
P/B
4.19
Dividend yield
1.2%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 348 Cr | 579 Cr | 798 Cr | 253 Cr | 231 Cr | 488 Cr | 307 Cr | 402 Cr | 549 Cr | 556 Cr | 545 Cr | 619 Cr |
| Operating expenses (approx.) | 170 Cr | 283 Cr | 424 Cr | 163 Cr | 133 Cr | 272 Cr | 174 Cr | 318 Cr | 431 Cr | 435 Cr | 448 Cr | 539 Cr |
| EBITDA | 178 Cr | 295 Cr | 375 Cr | 90 Cr | 98 Cr | 216 Cr | 133 Cr | 84 Cr | 118 Cr | 121 Cr | 97 Cr | 80 Cr |
| OPM % | 51.1% | 51.1% | 47.0% | 35.7% | 42.5% | 44.3% | 43.4% | 20.9% | 21.5% | 21.8% | 17.7% | 13.0% |
| Other income | 11 Cr | 31 Cr | 45 Cr | 17 Cr | 18 Cr | 32 Cr | 16 Cr | 11 Cr | 14 Cr | 16 Cr | 6 Cr | -2 Cr |
| Interest | 1 Cr | 2 Cr | 3 Cr | 2 Cr | 2 Cr | 3 Cr | 3 Cr | 6 Cr | 10 Cr | 9 Cr | 9 Cr | 9 Cr |
| Depreciation | 13 Cr | 24 Cr | 37 Cr | 17 Cr | 13 Cr | 30 Cr | 20 Cr | 27 Cr | 45 Cr | 44 Cr | 47 Cr | 51 Cr |
| Profit before tax | 164 Cr | 269 Cr | 335 Cr | 71 Cr | 83 Cr | 183 Cr | 110 Cr | 52 Cr | 63 Cr | 84 Cr | 41 Cr | 20 Cr |
| Tax % | 26.4% | 25.7% | 26.3% | 24.7% | 26.9% | 21.8% | 24.1% | 24.9% | 26.1% | 20.7% | 28.5% | 58.3% |
| Net profit | 121 Cr | 200 Cr | 247 Cr | 53 Cr | 61 Cr | 143 Cr | 83 Cr | 39 Cr | 46 Cr | 66 Cr | 29 Cr | 8 Cr |
| EPS (₹) | ₹4.74 | ₹7.86 | ₹9.70 | ₹2.10 | ₹2.39 | ₹5.62 | ₹3.26 | ₹1.65 | ₹1.28 | ₹1.94 | ₹0.96 | ₹0.51 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 834 Cr | 1,010 Cr | 1,320 Cr | 1,340 Cr | 1,051 Cr | 1,198 Cr | 2,269 Cr | Sign in for TTM |
| Operating expenses (approx.) | 431 Cr | 555 Cr | 648 Cr | 774 Cr | 646 Cr | 764 Cr | 1,837 Cr | Sign in for TTM |
| EBITDA | 403 Cr | 455 Cr | 672 Cr | 567 Cr | 406 Cr | 434 Cr | 432 Cr | Sign in for TTM |
| OPM % | 48.4% | 45.0% | 50.9% | 42.3% | 38.6% | 36.2% | 19.0% | Sign in for TTM |
| Other income | 18 Cr | 14 Cr | 92 Cr | 46 Cr | 62 Cr | 59 Cr | 34 Cr | Sign in for TTM |
| Interest | 23 Cr | 9 Cr | 6 Cr | 5 Cr | 7 Cr | 12 Cr | 37 Cr | Sign in for TTM |
| Depreciation | 24 Cr | 32 Cr | 39 Cr | 48 Cr | 55 Cr | 77 Cr | 187 Cr | Sign in for TTM |
| Profit before tax | 356 Cr | 414 Cr | 626 Cr | 560 Cr | 406 Cr | 344 Cr | 207 Cr | Sign in for TTM |
| Tax % | 24.6% | 25.4% | 34.1% | 26.5% | 26.0% | 23.0% | 27.5% | Sign in for TTM |
| Net profit | 317 Cr | 362 Cr | 454 Cr | 411 Cr | 300 Cr | 265 Cr | 150 Cr | Sign in for TTM |
| EPS (₹) | ₹24.91 | ₹14.23 | ₹17.83 | ₹16.16 | ₹11.80 | ₹10.52 | ₹4.69 | Sign in for TTM |
| Dividend payout % | — | — | 22.4% | 49.5% | 0.0% | 0.0% | 0.0% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 13 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 38 Cr |
| Reserves | 832 Cr | 1,155 Cr | 0.0000 Cr | 1,710 Cr | 2,025 Cr | 1,671 Cr | 3,996 Cr |
| Borrowings | 186 Cr | 141 Cr | 96 Cr | 69 Cr | 39 Cr | 72 Cr | 119 Cr |
| Other liabilities | 142 Cr | 152 Cr | 189 Cr | 161 Cr | 165 Cr | 1,119 Cr | 1,577 Cr |
| Total liabilities | 1,111 Cr | 1,359 Cr | 1,805 Cr | 1,966 Cr | 2,254 Cr | 3,032 Cr | 5,730 Cr |
| Fixed assets (net) | 353 Cr | 437 Cr | 531 Cr | 584 Cr | 567 Cr | 995 Cr | 1,990 Cr |
| CWIP | 102 Cr | 96 Cr | 30 Cr | 165 Cr | 179 Cr | 255 Cr | 173 Cr |
| Investments | 276 Cr | 426 Cr | 600 Cr | 536 Cr | 904 Cr | 337 Cr | 529 Cr |
| Other assets | 392 Cr | 565 Cr | 1,109 Cr | 1,011 Cr | 84,347 Cr | 854 Cr | 1,804 Cr |
| Total assets | 1,111 Cr | 1,359 Cr | 1,805 Cr | 1,966 Cr | 2,254 Cr | 3,032 Cr | 5,730 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | 330 Cr | 451 Cr | 358 Cr | 288 Cr | 368 Cr |
| Cash from investing | — | — | -136 Cr | -195 Cr | -362 Cr | -255 Cr | -255 Cr |
| Cash from financing | — | — | -156 Cr | -236 Cr | -14 Cr | 3 Cr | -165 Cr |
| Net cash flow | — | — | 37 Cr | 20 Cr | -18 Cr | 36 Cr | -51 Cr |
| Free cash flow (OCF − Capex) | — | — | 255 Cr | 165 Cr | 307 Cr | 132 Cr | 148 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2020Standalone only | Mar 2021Standalone only | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | 44.9% | 35.8% | 2485.4% | 28.8% | 16.8% | 18.6% | 5.9% |
| ROE % | 37.5% | 30.7% | 0.0% | 23.7% | 0.0% | 14.6% | 4.4% |
| Debtor days | 51 | 37 | 65 | 30 | 46 | — | — |
| Inventory days | 266 | 236 | 225 | 265 | 317 | 272 | 290 |
| Days payable | 108 | 97 | 84 | 55 | 58 | — | — |
| Cash conversion cycle | 209 | 175 | 206 | 240 | 306 | 272 | 290 |
| Debt / equity | 0.24 | 0.13 | 0.06 | 0.04 | 0.02 | 0.04 | 0.03 |
| Current ratio | 1.95 | 2.57 | 5.31 | 6.37 | 11.82 | 2.34 | 2.78 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.0077 | -0.02 | -0.03 | 0.16 |
Compare with peers
Loading peers…